Rocket Pharmaceuticals
RCKT
15 hedge funds and large institutions have $52.5M invested in Rocket Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
59.34% more ownership
Funds ownership: 0% → 59.34% (+59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DPA
Devon Park Associates
|
+$19M |
| 2 |
Rho Capital Partners
New York
|
+$16.8M |
| 3 |
Jennison Associates
New York
|
+$5.87M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$4.89M |
| 5 |
Pentwater Capital Management
Naples,
Florida
|
+$4.11M |
Top Sellers
RCKT Hedge Fund Activity: Q1 2015 in Review
15 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q1 2015, worth a combined $52.5M.
Buyers outnumbered sellers: 15 funds opened new RCKT positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Devon Park Associates, opening a new position worth an estimated $19M.
- 15 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $52.5M of Rocket Pharmaceuticals stock for Q1 2015.
- 15 funds opened new Rocket Pharmaceuticals positions in Q1 2015 and 0 closed out, a net change of +15 holders.
- The largest Rocket Pharmaceuticals buyer in Q1 2015 was Devon Park Associates, an estimated $19M added.
Based on aggregated 13F filings for Q1 2015.